M

Medical University of Innsbruck | Neurology Clinic

Research site
(Unclaimed)
Location
Anichstraße 35, Innsbruck, Tyrol, Austria
Site insights

Top conditions

COVID-19 (7 trials)

Bone Fractures (4 trials)

Ovarian Cancer (3 trials)

Coronary Artery Disease (3 trials)

Ovarian Epithelial Carcinoma (3 trials)

Top treatments

BI 425809
Nintedanib
Dabigatran Etexilate
Atezolizumab
Lucitanib
Bevacizumab
Ritonavir
Apixaban
Chemotherapy+Bevacizumab
BI 685509

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

12 of 77
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay)

The purpose of this first-in-human (FIH) study of [177Lu]-NeoB is to characterize the safety, tolerability, pharmacokinetics (PK) as well as the dist...

Enrolling
Neoplasms
Drug: [68Ga]-NeoB
Drug: [177Lu]-NeoB

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will ha...

Enrolling
Ulcerative Colitis Chronic
Ulcerative Colitis
Drug: Mirikizumab

This study is open to adults with different types of advanced cancer (solid tumours) that are accessible for injection. People for whom previous trea...

Enrolling
Solid Tumors
Drug: ezabenlimab
Drug: BI 1831169

This study is open to adults with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver). The purpose of this st...

Active, not recruiting
Hypertension, Portal
Drug: Placebo matching Avenciguat (BI 685509)
Drug: Avenciguat (BI 685509)

The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid)...

Active, not recruiting
Cancer-associated Thrombosis
Drug: Apixaban 5 MG

This is a phase III, randomized, double-blinded, comparative, multi-centre study to assess the efficacy of atezolizumab in combination with platinum-...

Active, not recruiting
Ovarian Cancer
Drug: placebo + avastin + platinum-based chemotherapy
Drug: atezolizumab + avastin + platinum-based chemotherapy

Atezolizumab is an engineered humanised monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1...

Active, not recruiting
Endometrial Cancer
Drug: Paclitaxel
Drug: Carboplatin

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Example...

Enrolling
Schizophrenia
Drug: Placebo
Drug: iclepertin

Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk...

Enrolling
Prematurity
Vascular Aging
Dietary Supplement: Humavant

The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedur...

Enrolling
Mitral Valve Regurgitation
Device: Epygon™ Transcatheter Mitral Valve System

This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and sy...

Enrolling
MSA - Multiple System Atrophy
Symptomatic Neurogenic Orthostatic Hypotension
Drug: Placebo
Drug: Ampreloxetine

Safety and Performance Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the reduction of pathogen load from the blood in sept...

Enrolling
Bloodstream Infection
Device: Seraph 100,The Microbind Affinity Blood Filter

Trial sponsors

M

Medical University Innsbruck (19 trials)

Boehringer Ingelheim logo

Boehringer Ingelheim (12 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems